First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Condition:   Breast Cancer Interventions:   Drug: RGT-419B;   Drug: RGT-419B in combination with hormonal therapy Sponsor:   Regor Pharmaceuticals Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials